What is Cempra?
Headquartered in Chapel Hill, North Carolina, Cempra, Inc. operates as a specialized biopharmaceutical entity focused on the development of next-generation anti-infectives. The company's core value proposition centers on its proprietary macrolide platform, which supports the development of solithromycin and fusidic acid. These candidates are currently undergoing rigorous Phase III clinical trials targeting community-acquired bacterial pneumonia and acute bacterial skin infections. By leveraging advanced oral, intravenous, and suspension delivery mechanisms, Cempra aims to bridge significant gaps in current treatment protocols for both adult and pediatric populations. The firm's strategic positioning is further bolstered by its collaborative research agreements, which facilitate the expansion of its therapeutic reach into non-infectious disease programs, including treatments for diabetic gastroparesis.
How much funding has Cempra raised?
Cempra has raised a total of $194M across 8 funding rounds:
Series B
$10M
Private Equity
$25.5M
Series C
$46M
Debt
$5M
Stock Offering
$50.4M
Private Equity
$25.1M
Private Equity
$10M
Series A
$22M
Series B (2007): $10M with participation from Intersouth Partners, I. Wistar Morris III, Aisling Capital, and Optimer Pharmaceuticals
Private Equity (2009): $25.5M, investors not publicly disclosed
Series C (2009): $46M, investors not publicly disclosed
Debt (2011): $5M, investors not publicly disclosed
Stock Issuance/Offering (2012): $50.4M, investors not publicly disclosed
Private Equity (2012): $25.1M, investors not publicly disclosed
Private Equity (2016): $10M led by Toyama Chemical
Series A (2020): $22M supported by I. Wistar Morris and Intersouth Partners
Key Investors in Cempra
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies.
Toyama Chemical
Toyama Chemical Co., Ltd. is a core company of the Fujifilm Group responsible for the treatment area of Fujifilm's healthcare business, focusing on infectious and neurological diseases.
Intersouth Partners
Intersouth Partners is a venture capital firm that provides early-stage and growth-stage backing to companies within the life sciences and technology sectors.
What's next for Cempra?
With the recent influx of capital, Cempra is well-positioned to accelerate its late-stage clinical development programs and optimize its commercialization strategy. The company's roadmap emphasizes the successful completion of ongoing Phase III trials and the subsequent regulatory submission processes required for market entry. As the firm transitions from a research-heavy organization to a commercial-stage player, management will likely prioritize the scaling of its manufacturing capabilities and the strengthening of its intellectual property portfolio. Future growth will be driven by the successful deployment of its macrolide platform, with potential for further diversification into specialized gastrointestinal and inflammatory disease markets. The strategic focus remains on achieving international standards for drug efficacy and safety, ensuring that Cempra remains a pivotal contributor to the global healthcare landscape.
See full Cempra company page
